# INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees

> **NCT04906629** · PHASE1 · COMPLETED · sponsor: **University of Geneva, Switzerland** · enrollment: 46 (actual)

## Conditions studied

- Ebola Virus Disease

## Interventions

- **BIOLOGICAL:** INO-4201
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04906629
- **Lead sponsor:** University of Geneva, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-01-05
- **Final completion:** 2022-05-11
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-05-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906629, "INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04906629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*